← Back to Search

Other

PM14 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by PharmaMar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the date of first infusion of study treatment to the date of study termination, assessed up to 72 months
Awards & highlights

Study Summary

This trial is testing a new combination regimen for patients with advanced solid tumors.

Eligible Conditions
  • Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the date of first infusion of study treatment to the date of study termination, assessed up to 72 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the date of first infusion of study treatment to the date of study termination, assessed up to 72 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate
Patients with dose limiting toxicities
Secondary outcome measures
Clinical Benefit Rate
Duration of Response
Incidence of Treatment-Emergent Adverse Events
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: PM14Experimental Treatment1 Intervention
Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.

Find a Location

Who is running the clinical trial?

PharmaMarLead Sponsor
90 Previous Clinical Trials
11,387 Total Patients Enrolled
~20 spots leftby Jun 2025